Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders

Clinical Chemistry

Volumn 46, Issue 2, 2000, Pages 167-174

  Chang, Melissa H Y ^a,b   Bindloss, Colleen A ^a   Grabowski, Gregory A ^c   Qi, Xiaoyang ^c   Winchester, Bryan ^d   Hopwood, John J ^a   Meikle, Peter J ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; SPHINGOLIPID ACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE; HUMAN; IMMUNOASSAY; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; QUANTITATIVE ASSAY; STATISTICAL ANALYSIS;

EID: 0033977050     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.2.167     Document Type: Article

References (26)

1. 1. Hopwood JJ, Brooks DA. An introduction to the basic science and biology of the lysosome and storage diseases. In: Applegarth DA, Dimmick JE, Hall JG, eds. Organelle diseases. New York: Chapman & Hall Medical, 1997:7-35.
2. 2. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AC, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th ed., Vol. II. New York: McGraw-Hill, 1995:2465-94.
3. 3. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, et al. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987;316:971-7.
4. 4. Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993;328:1157-62.
5. 5. Hopwood JJ, Vellodi A, Scott HS, Morris CP, Litjens T, Clements PR, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis 1993;16:1024-33.
6. 6. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 1995;345:1398-402.
7. 7. Hoogerbrugge PM, Valerio D. Bone marrow transplantation and gene therapy for lysosomal storage diseases. Bone Marrow Transplant 1998;21:534-336.
8. 8. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher-disease - the first 5 years [Review]. Blood Rev 1998;12:115-33.
9. 9. Kakkis E, Muenzer J, Tiller G, Waber L, Belmont J, Passage M, et al. Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis I: results of a human clinical trial. The American Society of Human Genetics 48th Annual Meeting, October 27-31, 1998, Denver, Colorado:128.
10. 10. Taylor RM, Stewart GJ, Farrow BR. Improvement in the neurologic signs and storage lesions of fucosidosis in dogs given marrow transplants at an early age. Transplant Proc 1989;21:3818-9.
11. 11. Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Investig 1997;99:651-62.
12. 13. Vogler C, Levy B, Galvin NJ, Thorpe C, Sands MS, Barker JE, et al. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 1999;45: 838-44.
13. 13. Meikle PJ, Brooks DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, et al. Diagnosis of lysosomal storage disorders: evaluation of a lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 1997;43:1325-35.
14. 14. Hua CT, Hopwood JJ, Carlsson SR, Harris RJ, Meikle PJ. Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders. Clin Chem 1998;44: 2094-102.
15. 15. O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991; 5:301-8.
16. 16. Leonova T, Qi X, Bencosme A, Ponce E, Sun Y, Grabowski GA. Proteolytic processing patterns of prosaposin in insect and mammalian cells. J Biol Chem 1996;271:17312-20.
17. 17. Bradova V, Smid F, Ulrich Bott B, Roggendorf W, Paton BC, Harzer K. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingoli. Hum Genet 1993;92:143-52.
18. 18. Inui K, Wenger DA. Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases. J Clin Investig 1983;72:1622-8.
19. 19. Morimoto S, Martin BM, Yamamoto Y, Kretz KA, O'Brien JS, Kishimoto Y. Saposin A: second cerebrosidase activator protein. Proc Natl Acad Sci U S A 1989;86:3389-93.
20. 20. Kampine JP, Brady RO, Kanfer JN, Feld M, Shapiro D. Diagnosis of Gaucher disease and Niemann-Pick disease with small samples of venous blood. Science 1967;155:86-8.
21. 21. Qi X, Leonova T, Grabowski GA. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid β-glucosidase. J Biol Chem 1994;269:16746-53.
22. 22. Morimoto S, Yamamoto Y, O'Brien JS, Kishimoto Y. Determination of saposin proteins (sphingolipid activator proteins) in human tissues. Anal Biochem 1990;190:154-7.
23. 23. Tayama M, O'Brien JS, Kishimoto Y. Distribution of saposins (sphingolipid activator proteins) in tissues of lysosomal storage disease patients. J Mol Neurosci 1992;3:171-5.
24. 24. Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N. Prenatal mucopolysaccharidosis II (Hunter): a pathogenetic study. Pediatr Res 1980;14:749-56.
25. 25. Crow J, Gibbs DA, Cozens W, Spellacy E, Watts RW. Biochemical and histopathological studies on patients with mucopolysaccharidoses, two of whom had been treated by fibroblast transplantation. J Clin Pathol 1983;36:415-30.
26. 26. Vogler C, Birkenmier EH, Sly WS, Levy B, Pegors C, Kyle JW, et al. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in β-glucuronidase-deficient mice. Am J Pathol 1990;136:207-17.